EUR 2.85
(-2.9%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -4.2 Million CAD | 198.78% |
2022 | -33.64 Million CAD | 108.5% |
2021 | 4.82 Million CAD | -21.21% |
2020 | 8.67 Million CAD | 131.02% |
2019 | -19.73 Million CAD | -396.95% |
2018 | -3.97 Million CAD | -452.65% |
2017 | 963.32 Thousand CAD | -33.6% |
2016 | 1.69 Million CAD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q3 | 10.17 Million CAD | 6.8% |
2024 Q2 | 10.51 Million CAD | 1.27% |
2024 Q1 | 9.52 Million CAD | 137.87% |
2023 Q3 | 5.26 Million CAD | -14.69% |
2023 Q2 | 6.17 Million CAD | 22.77% |
2023 Q1 | 5.02 Million CAD | 6.05% |
2023 FY | - CAD | 198.78% |
2023 Q4 | 6.97 Million CAD | 32.49% |
2022 Q3 | 2.47 Million CAD | 172.99% |
2022 Q1 | 1.92 Million CAD | 144.43% |
2022 Q4 | 4.74 Million CAD | 91.52% |
2022 FY | - CAD | 108.5% |
2022 Q2 | 907 Thousand CAD | -52.98% |
2021 Q1 | 3.44 Million CAD | 579.68% |
2021 Q3 | 1.45 Million CAD | -58.07% |
2021 Q4 | -4.34 Million CAD | -399.04% |
2021 Q2 | 3.46 Million CAD | 0.49% |
2021 FY | - CAD | -21.21% |
2020 FY | - CAD | 131.02% |
2020 Q2 | 1.93 Million CAD | 251.45% |
2020 Q4 | 507 Thousand CAD | -87.66% |
2020 Q1 | -1.27 Million CAD | 83.37% |
2020 Q3 | 4.1 Million CAD | 112.13% |
2019 Q3 | -3.47 Million CAD | 17.81% |
2019 FY | - CAD | -396.95% |
2019 Q4 | -7.69 Million CAD | -121.07% |
2019 Q2 | -4.23 Million CAD | 9.75% |
2019 Q1 | -4.69 Million CAD | -37.44% |
2018 Q3 | -637 Thousand CAD | 6.32% |
2018 Q2 | -680 Thousand CAD | -238.9% |
2018 FY | - CAD | -452.65% |
2018 Q4 | -3.41 Million CAD | -435.7% |
2018 Q1 | 489.56 Thousand CAD | 49.61% |
2017 Q3 | 763.63 Thousand CAD | 0.0% |
2017 Q4 | 327.22 Thousand CAD | -57.15% |
2017 FY | - CAD | -33.6% |
2016 FY | - CAD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Newron Pharmaceuticals S.p.A. | -11.71 Million EUR | 64.164% |
Redcare Pharmacy NV | 58.17 Million EUR | 107.219% |